{"generic":"Mifamurtide","drugs":["Mifamurtide"],"mono":{"0":{"id":"jxums0","title":"Generic Names","mono":"Mifamurtide"},"1":{"id":"jxums1","title":"Dosing and Indications","sub":[{"id":"jxums1b4","title":"Adult Dosing","mono":"<ul><li>mifamurtide has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>use in adults older than 30 years not recommended<\/li><li><b>Osteosarcoma of bone, High-grade, resectable, non-metastatic; adjuvant therapy after macroscopically complete surgical resection:<\/b> (younger than 30 years) 2 mg\/m(2) infused IV over 1 hour twice weekly, separated by 3 days, for 12 weeks, then once weekly for additional 24 weeks; total 48 infusions in 36 weeks (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"jxums1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in pediatric patients younger than 2 years<\/li><li><b>Osteosarcoma of bone, High-grade, resectable, non-metastatic; adjuvant therapy after macroscopically complete surgical resection:<\/b> (2 years or older) 2 mg\/m(2) infused IV over 1 hour twice weekly, separated by 3 days, for 12 weeks, then once weekly for additional 24 weeks; total 48 infusions in 36 weeks (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"jxums1b6","title":"Dose Adjustments","mono":"<ul><li><b>concomitant use with renally toxic chemotherapy agents:<\/b> no dose adjustment necessary<\/li><li><b>concomitant use with hepatotoxic chemotherapy agents:<\/b> no dose adjustment necessary<\/li><\/ul>"},{"id":"jxums1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Osteosarcoma of bone, High-grade, resectable, non-metastatic; adjuvant therapy after macroscopically complete surgical resection<br\/>"}]},"3":{"id":"jxums3","title":"Contraindications\/Warnings","sub":[{"id":"jxums3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to mifamurtide or any product excipients<\/li><li>concomitant use with cyclosporine or other calcineurin inhibitors<\/li><li>concomitant use with high-dose NSAIDs or cyclooxygenase inhibitors<\/li><\/ul>"},{"id":"jxums3b10","title":"Precautions","mono":"<ul><li>allergic reactions, serious (ie, shortness of breath, grade 4 hypertension), have occurred; may be difficult to differentiate from exaggerated inflammatory response; monitoring recommended<\/li><li>autoimmune, inflammatory, or other collagen diseases, history; increased risk of pronounced inflammatory response; monitoring recommended<\/li><li>concomitant use with chronic or routine corticosteroid therapy should be avoided<\/li><li>hepatic impairment; monitoring recommended<\/li><li>neutropenia, generally in combination with chemotherapy, has occurred; monitoring recommended if fever present; assess for sepsis with persistent (greater than 8 hours) fever or chills after administration<\/li><li>renal impairment; monitoring recommended<\/li><li>respiratory distress has been reported; increased risk with history of asthma or COPD; consider prophylaxis with bronchodilators; discontinue use if suspected<\/li><li>venous thrombosis, vasculitis, or unstable cardiovascular disorders, history; symptoms may persist and worsen during therapy; delay or discontinuation of therapy may be required; monitoring recommended<\/li><\/ul>"},{"id":"jxums3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jxums3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"jxums5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (11%), Tachycardia (More than 50%)<\/li><li><b>Dermatologic:<\/b>Hyperhidrosis (11%)<\/li><li><b>Endocrine metabolic:<\/b>Hypothermia (23%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (17%), Diarrhea (13%), Loss of appetite (21%), Nausea (57%), Vomiting (44%)<\/li><li><b>Hematologic:<\/b>Anemia (10% or greater), Neutropenic disorder<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (10%), Backache (15%), Myalgia (31%), Pain in limb (12%)<\/li><li><b>Neurologic:<\/b>Asthenia (13%), Dizziness (17%), Headache (50%)<\/li><li><b>Respiratory:<\/b>Cough (18%), Dyspnea (21%), Tachypnea (13%)<\/li><li><b>Other:<\/b>Fatigue (53%), Fever (85%), Malaise (13%), Pain (15%), Shivering (89%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Cellulitis (1% to less than 10%)<\/li><li><b>Hematologic:<\/b>Febrile neutropenia (1% to less than 10%), Myelodysplastic syndrome (2.1%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction, Inflammatory disorder<\/li><li><b>Otic:<\/b>Hearing loss (1% to 12%)<\/li><li><b>Other:<\/b>Cyanosis (1% to less than 10%), Sepsis (1% to less than 10%)<\/li><\/ul>"},"6":{"id":"jxums6","title":"Drug Name Info","sub":{"2":{"id":"jxums6b19","title":"Class","mono":"Immune Stimulant<br\/>"},"3":{"id":"jxums6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jxums9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>do not administer as a bolus injection<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>allow vial to reach room temperature before reconstitution (approximately 30 minutes)<\/li><li>withdraw 50 mL NS from 100-mL NS infusion bag and reconstitute using filter provided to bring vial concentration to 0.08 mg\/mL<\/li><li>filter and syringe must not be removed from vial until reconstitution process completed<\/li><li>after reconstitution, let vial stand for 1 minute, then shake vigorously for 1 minute for liposome formation<\/li><li>withdraw desired dose, inject back into original infusion bag, and infuse IV over 1 hour<\/li><li>administer prepared solution immediately if possible; reconstituted vial contents stable for 6 hours at room temperature (between approximately 25 to 25 degrees C)<\/li><li>separate administration times of mifamurtide and doxorubicin or other lipophilic agents<\/li><\/ul><\/li><\/ul>"}}}